Background:  This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK- 1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF. Sponsor: Merck Sharp & Dohme Corp. Trial Registration No: NCT02861534 (clinicaltrials.gov) Link  Trial Status: recruiting, randomized worldwide Enrolling Centers:  Worldwide: 41 countries Core Study Team: 
© Christian Mueller, 2012 - 2018 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: April 2018
Jasmin Martin Brigitte Fitze Rahel Isenrich Home News Team Studies Publications Events Cooperations Contact Max Rieger Bettina Glatz VICTORIA Beate Hartmann Ph.D. Dayana Flores Stephanie Dörflinger Romy Mayr